Proteomic Insights: Characterizing the Anti-Glioma and Anti-Breast Cancer Peptidome of Buthidae Scorpion Venoms

Keywords: Scorpion Venom Proteomics, Buthidae Venoms, Anti-Glioma Peptides, Anti-Breast Cancer Compounds, Peptidome Characterization

Article Title: Proteomic Insights: Characterizing the Anti-Glioma and Anti-Breast Cancer Peptidome of Buthidae Scorpion Venoms

Meta Description: Gain proteomic insights into Buthidae Scorpion Venoms with anti-glioma and anti-breast cancer activity. Access characterized venom libraries from Blue Eyes Biotech for targeted drug discovery.

(Article Content)

The limited diversity of approved anticancer peptides underscores the need for comprehensive exploration of novel natural sources

, particularly those with evolved biological activity against specific cancer types. Scorpion Venoms from the Buthidae family represent

particularly promising sources due to their complex peptide composition and known ion channel targeting capabilities, though their full

anticancer potential remains largely unexplored. The major technical challenge in harnessing Buthidae Scorpion Venoms lies in the

comprehensive characterization of their peptidome and the correlation of specific peptide sequences with anticancer activity against

defined cancer types. Advanced proteomic approaches are required to deconvolute these complex mixtures and identify lead candidates

efficiently. For drug discovery organizations, the procurement of Buthidae Scorpion Venoms should include detailed proteomic

characterization data, activity profiles against relevant cancer cell lines, and information on geographical origin and collection methods.

Our extensive proteomic analysis of Buthidae Scorpion Venoms from different geographical regions has identified over 200 unique peptides

, with 35 showing significant activity against glioma and breast cancer cell lines. Using LC-MS/MS and de novo sequencing,

we characterized peptide masses ranging from 3-8 kDa with distinctive cysteine frameworks. Several newly identified peptides

demonstrated exceptional potency against glioma stem cells, with 80% reduction in neurosphere formation at nanomolar concentrations.

Parallel studies in breast cancer models showed specific fractions inhibiting metastasis-related processes by over 70% in invasion and

migration assays. These findings substantially expand the known anticancer peptide library from Scorpion Venoms.

Blue Eyes Biotech Co., Ltd. maintains the world's most comprehensive characterized Scorpion Venom library, with detailed proteomic and

activity data for efficient lead identification. Our extensively documented venom collections accelerate early-stage discovery while reducing

research costs. To access our characterized venom libraries or request custom screening services, contact [email protected] or

explore our database at www.blueeyes-bio.com.